Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 409 ILLINOIS STREET SAN FRANCISCO CA 94158 |
Tel: | N/A |
Website: | https://www.fibrogen.com |
IR: | See website |
Key People | ||
Thane Wettig Chief Executive Officer, Director, Chief Commercial Officer | Juan Graham Chief Financial Officer | Deyaa Adib Senior Vice President and Chief Medical Officer | Christine L. Chung Senior Vice President, China Operations |
Business Overview |
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody. |
Financial Overview |
For the fiscal year ended 31 December 2023, FibroGen Inc revenues increased 5% to $147.8M. Net loss decreased 3% to $284.2M. Revenues reflect China segment increase of 29% to $109.4M, Japan - Related Party segment increase of 63% to $15.9M. Lower net loss reflects Stock-based Compensation in R&D decrease of 27% to $25.5M (expense), Stock-based Compensation in SGA decrease of 18% to $25.3M (expense). |
Employees: | 486 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $147.75M as of Dec 31, 2023 |
EBITDA (TTM): | -$259.28M as of Dec 31, 2023 |
Net annual income (TTM): | -$284.23M as of Dec 31, 2023 |
Free cash flow (TTM): | -$317.54M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 98,771,247 as of Jan 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |